Skip to content
Catalyst
Search

Papers/PMID:39125322

The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.

Nutrients2024The record

6 findings · 1 compound · 6 endpoints

What it reported

How to read these marks

What moved

6 findings

  • curcumin — decreases interleukin-6 concentration

    Evidence strength: moderate.Findingreplicated ×8
    “Additionally, the levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month assessments (Table 2, Supplementary Figure S3K–M).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled (HbA1c below 6.5%), BMI 23 or above; difference at 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink

  • curcumin — decreases tumour necrosis factor alpha concentration

    Evidence strength: moderate.Findingreplicated ×6
    “Additionally, the levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month assessments (Table 2, Supplementary Figure S3K–M).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled (HbA1c below 6.5%), BMI 23 or above; difference at 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink

  • curcumin — decreases fasting blood glucose

    Evidence strength: moderate.Findingreplicated ×5
    “The means of diabetes-related blood chemistries, such as HbA1c and FPG, were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month visits (Table 2).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled at entry (FPG below 110 mg/dL), BMI 23 or above; difference at 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink

  • curcumin — decreases glycated haemoglobin (HbA1c)

    Evidence strength: moderate.Findingreplicated ×4
    “The means of diabetes-related blood chemistries, such as HbA1c and FPG, were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month visits (Table 2).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled at entry (HbA1c below 6.5%), BMI 23 or above; difference at 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink

  • curcumin — decreases HOMA-IR

    Evidence strength: moderate.Findingreplicated ×3
    “Insulin resistance, measured via HOMA-IR, was significantly lower in the curcumin-treated group than in the placebo group at all follow-up assessments (3, 6, 9, and 12 months; Supplementary Figure S3I).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled (HbA1c below 6.5%), BMI 23 or above; difference at 3, 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink

  • curcumin — decreases waist circumference

    Evidence strength: limited.Finding
    “The means of waist circumference, total body fat, and visceral fat were significantly lower in the curcumin-treated group than in the placebo group at the 6-, 9-, and 12-month visits (Table 2).”
    Quoted verbatim from The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial..
    Study
    RCT
    Dose
    curcuminoid extract 250 mg per capsule, three capsules twice daily after meals (six capsules a day) for 12 months
    Population
    Thai adults with type 2 diabetes diagnosed within the past year, well controlled (HbA1c below 6.5%), BMI 23 or above; difference at 6, 9 and 12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2024PMID:3912532210.3390/nu16152441Industry fundedPermalink